Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Apr 15, 2025; 17(4): 102038
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.102038
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.102038
Comparing transarterial chemoembolization alone to combined transarterial chemoembolization and radiofrequency ablation in primary hepatocellular carcinoma treatment
Jing Fei, Li-Wen Qi, Yuan Liu, Min Shu, Wen-Qiang Mo, Department of Oncology, The First Affiliated Hospital of Shihezi University, Shihezi 832008, Xinjiang Uygur Autonomous Region, China
Author contributions: Fei J and Qi LW conceived the study and played a significant role in the literature search, data extraction, quality assessment, data analysis, and manuscript preparation; Fei J and Liu Y contributed to improving the article’s language and style, as well as protocol preparation; Shu M and Mo WQ assisted in the analysis with constructive discussions; Fei J revised the manuscript and approved the final version.
Institutional review board statement: This study was approved by the Ethics Committee of the First Affiliated Hospital of Shihezi University.
Informed consent statement: Written informed consent for publication was obtained from all patients and/or their families included in this retrospective analysis.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: The data sets generated and analyzed during this study are not public, but under reasonable requirements, the correspondence author can provide.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jing Fei, MM, Doctor, Department of Oncology, The First Affiliated Hospital of Shihezi University, No. 107 North Second Road, Shihezi 832008, Xinjiang Uygur Autonomous Region, China. feij_xj@163.com
Received: October 6, 2024
Revised: January 8, 2025
Accepted: January 21, 2025
Published online: April 15, 2025
Processing time: 169 Days and 21.1 Hours
Revised: January 8, 2025
Accepted: January 21, 2025
Published online: April 15, 2025
Processing time: 169 Days and 21.1 Hours
Core Tip
Core Tip: Our study addresses a critical aspect of hepatocellular carcinoma (HCC) treatment, comparing the outcomes of transarterial chemoembolization (TACE) alone vs the combination of TACE with percutaneous radiofrequency ablation. With a robust retrospective analysis of 106 patients, our findings highlight significant enhancements in treatment efficacy and survival rates when these therapies are combined, thus proposing a pivotal shift in therapeutic strategies for patients with unresectable HCC.